Consensus AbbVie Inc.

Stocks

ABBV

US00287Y1091

Pharmaceuticals

Delayed NYSE 16:03:55 2026-09-04 EDT			5-day change	1st Jan Change
256.46 ^USD	-1.44%		+0.38%	+12.24%

09-03	AbbVie Announces Positive Topline Results From The Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma	CI
09-03	AbbVie Inc. completed the acquisition of Apogee Therapeutics, Inc. from Fairmount Healthcare Fund II L.P managed by Fairmount Funds Management LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P managed by Venrock Management, LLC and other shareholders.	CI

Evolution of the Average Target: AbbVie Inc.

Evolution of the Target Price: AbbVie Inc.

Changes in Analyst Recommendations: AbbVie Inc.

e65df14dc93b3eb868e3c17e8d.OVv5EUsDseQ34VAfdsEmS4hPJwbAT0v2uEkKw2DuB7U.U2OeQjg7xJcBsjldQYdKMt8NFVCtLh-E7Qw4iBmJN8BrGLRaCXfFrnKNaA~68b615f978b163d25178051632649b66

Analysts' recommendations: AbbVie Inc.

08-20	Piper Sandler Adjusts Price Target on AbbVie to $303 From $298, Maintains Overweight Rating	MT
08-17	Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating	MT
08-13	Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300	MT
08-11	BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating	MT
08-05	Argus Lifts AbbVie Price Target to $270 From $250	MT
08-05	Leerink Partners Adjusts Price Target on AbbVie to $279 From $245	MT
08-04	Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating	MT
08-04	Rothschild & Co Redburn Adjusts Price Target on AbbVie to $285 From $284, Maintains Buy Rating	MT
08-03	AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says	MT
08-03	Oppenheimer Adjusts AbbVie Price Target to $258 From $244, Maintains Neutral Rating	MT
08-03	Canaccord Genuity Adjusts AbbVie Price Target to $290 From $282, Maintains Buy Rating	MT
07-31	JPMorgan Adjusts Price Target on AbbVie to $285 From $280	MT
07-28	Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating	MT
07-22	Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating	MT
07-15	Citigroup Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT
07-13	BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating	MT
07-13	UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	BofA Securities Adjusts AbbVie Price Target to $276 From $234	MT
07-10	AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says	MT
07-10	RBC Raises Price Target on AbbVie to $280 From $260, Keeps Outperform Rating	MT
07-10	Wells Fargo Adjusts Price Target on AbbVie to $295 From $260	MT
07-09	JPMorgan Adjusts Price Target on AbbVie to $280 From $260	MT
07-09	Guggenheim Adjusts Price Target on AbbVie to $261 From $249	MT
07-08	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBVIE INC.					+7.85%
	ELI LILLY AND COMPANY					+14.46%
	JOHNSON & JOHNSON					+0.15%
	ROCHE HOLDING AG					+3.73%
	NOVARTIS AG					-3.13%
	ASTRAZENECA PLC					+31.17%
	AMGEN INC.					-10.87%
	NOVO NORDISK A/S					+3.62%
	GILEAD SCIENCES, INC.					+4.25%
	PFIZER INC.					+0.55%
	Average					+5.18%
	Weighted average by Cap.					+6.70%